Meta Materials (MMAT) Corporate Presentation from NobleCon18News and Market Data on Meta MaterialsNobleCon 18 Complete Rebroadcast
|
Access to Exclusive Content. FREE for Registered Users Only.
Join the Channelchek Investor Community to access equity research, video content, events, and much more. All at no cost.


Welcome to the Channelchek Investor Community
We’ve updated the entire site to bring you faster navigation and increased content at every level. Channelchek is now North America’s leading platform for access to regulated and independent company sponsored equity research.
Don't have an account? Join
Forgot passwordBy clicking “Log In” you agree to Channelchek.com Terms of Use and acknowledge that Channelchek.com Privacy Policy applies to you.
Related News

10/13/2026
Health
Big Pharma’s Patent Cliff Could Spark a New Wave of Small-Cap Biotech Acquisitions
The biotechnology sector could be approaching another wave of merger and acquisition activity as major pharmaceutical companies confront a growing challenge: the expiration of patent protection on blockbuster medications. With...
3 min read

10/13/2026
Basic Materials
Critical Minerals Race Fuels Mining Deals as Companies Move to Secure Copper and Rare Earth Supplies
The global race to secure critical minerals is driving renewed merger and acquisition activity across the mining industry, as companies seek greater control over copper, rare earth elements, and other...
3 min read

10/13/2026
Health
Release – NeuroSense Secures Nasdaq Hearing Date as PrimeC Approaches Key Regulatory and Funding Milestones
NeuroSense Therapeutics Ltd. (NASDAQ: NRSN) (“NeuroSense” or the “Company”), a late-stage clinical biotechnology company focused on developing disease-modifying treatments for neurodegenerative diseases, today announced that its hearing before the Nasdaq Hearings...
7 min read

10/13/2026
Health
Release – Phase II Clinical Trial of NV-387 Oral Gummies as Treatment of Ebola Progressing Well, Says NanoViricides
NanoViricides, Inc. (NYSE American:NNVC) (the “Company”), a clinical stage leader developing antiviral drugs that viruses cannot escape, said today that its Phase IIA Ebola Treatment Clinical Trial of NV-387 Oral...
15 min read
Inbox Intel from Channelchek.
Informed investors make more money. And it’s all about timing. Get it when it happens.